

Claims:

1. Use of an anti-FcRn antibody for the manufacture of a medicament for the treatment of myasthenia gravis (MG) , wherein at least six doses of the antibody are to be administered weekly, wherein each dose is 7mg/kg or 10mg/kg,
5 wherein the antibody is to be administered subcutaneously, and
wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.
2. The use according to claim 1 wherein the antibody is provided as a pharmaceutical composition comprising one or more of a pharmaceutically acceptable
10 excipient, diluent or carrier.
3. The use according to claim 2 wherein the pharmaceutical composition further comprises one or more other active ingredients.
4. The use according to any one of claims 1 to 3 wherein six weekly doses are to be administered, followed by one or more additional doses that are lower and/or less
15 frequent than the initial or six doses.
5. The use according to any one of claims 1 to 4 wherein the human is suffering from generalised MG which is classified as moderate to severe.
6. The use according to any one of claims 1 to 5 wherein the human is anti-AChR and/or anti-MuSK autoantibody-positive and optionally is being considered for treatment with
20 IVIg or plasma exchange.
7. An anti-FcRn antibody or antigen binding fragment thereof for use according to any one of claims 1-6 wherein each dose is provided as a fixed unit dose selected from 280mg, 420mg, 560mg, 840mg and 1120mg.
8. Use of an anti-FcRn antibody or antigen-binding fragment thereof in the manufacture
25 of a medicament for treating or preventing myasthenia gravis (MG) in a human in need thereof, wherein the medicament is to be administered to the human at least 3 doses, preferably at least 6 doses, wherein each dose is selected from 280mg, 315mg, 350mg, 385mg, 420mg, 455mg, 490mg, 525mg, 560mg, 595mg, 630mg, 665mg, 700mg, 735mg, 770mg, 805mg, 840mg, 875 mg, 910mg, 945mg, 980mg,
30 1015mg, 1050mg, 1085mg and 1120mg and wherein the anti-FcRn antibody or antigen binding fragment thereof comprises a heavy chain comprising the sequence given in SED

ID NO:29 and a light chain comprising the sequence given in SEQ ID NO:15, optionally each dose is administered weekly,

wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

- 5 9. Use of an anti-FcRn antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing myasthenia gravis (MG) in a human in need thereof, wherein the medicament is to be administered to the human at least 6 doses, wherein for a body weight of less than 50kg the dose is 280mg, for a body weight of equal to or greater than 50kg but less than 70kg the dose is 420mg, for a body weight of equal to or greater than 70kg but less than 100kg the dose is 560mg and for a body weight of equal to or greater than 100kg the dose is 840mg, optionally each dose is administered weekly,
- 10

wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.

- 15 10. Use of an anti-FcRn antibody or antigen-binding fragment thereof in the manufacture of a medicament for treating or preventing myasthenia gravis (MG) in a human in need thereof, wherein the medicament is to be administered to the human at least 6 doses and wherein for a body weight of less than 50kg the dose is 420mg, for a body weight of equal to or greater than 50kg but less than 70kg the dose is 560mg, for a body weight of equal to or greater than 70kg but less than 100kg the dose is 840mg and for a body weight of equal to or greater than 100kg the dose is 1120mg, optionally each dose is administered weekly,
- 20

wherein the antibody has a heavy chain comprising the sequence given in SEQ ID NO: 43 and a light chain comprising the sequence given in SEQ ID NO: 22.